CardioKinetix

CardioKinetix

Signal active

Organization

Contact Information

Overview

The Company, based in Menlo Park, has developed a novel transcatheter implant called the PARACHUTETM Ventricular Partitioning Device (PARACHUTETM). The PARACHUTETM intends to treat heart failure resulting from a heart attack or myocardial infarction in millions of patients worldwide by improving overall cardiac function.

About

Industries

Biotechnology, Health Care, Medical Device

Founded

2003

Employees

11-50

Headquarters locations

Menlo Park, California, United States, North America

Social

Profile Resume

CardioKinetix headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical Device sector. The company focuses on Biotechnology and has secured $8.1B in funding across 72 round(s). With a team of 11-50 employees, CardioKinetix is actively contributing to advancements in Biotechnology. Their latest funding round, Series E - CardioKinetix, raised $21.0M. Discover more about their projects, partnerships, and impact on our platform.

Employees

N/A

Funding Rounds

Funding rounds

6

Investors

4

Lead Investors

0

Total Funding Amount

$112.5M

Details

6

CardioKinetix has raised a total of $112.5M in funding over 6 rounds.

Announcement dateTransaction nameNumber of InvestorsMoney raisedLead Investor
2014Late Stage Venture50.0M
2013Late Stage Venture23.0M
2013Late Stage Venture4.0M
2011Late Stage Venture21.0M

Investors

CardioKinetix is funded by 45 investors.

Investor NameLead InvestorFunding RoundPartners
Casey Tansey-FUNDING ROUND - Casey Tansey21.0M
U.S. Venture Partners-FUNDING ROUND - U.S. Venture Partners21.0M
Rod Ferguson-FUNDING ROUND - Rod Ferguson21.0M
CardioKinetix-FUNDING ROUND - CardioKinetix21.0M